Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $1.7 million.

  • Puma Biotechnology's Share-based Compensation fell 1854.92% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year decrease of 2068.35%. This contributed to the annual value of $8.2 million for FY2024, which is 1953.74% down from last year.
  • Puma Biotechnology's Share-based Compensation amounted to $1.7 million in Q3 2025, which was down 1854.92% from $1.6 million recorded in Q2 2025.
  • Puma Biotechnology's Share-based Compensation's 5-year high stood at $18.2 million during Q2 2021, with a 5-year trough of $1.6 million in Q2 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $2.5 million (2023), whereas its average is $3.6 million.
  • As far as peak fluctuations go, Puma Biotechnology's Share-based Compensation surged by 7158.04% in 2021, and later tumbled by 8234.55% in 2022.
  • Puma Biotechnology's Share-based Compensation (Quarter) stood at $4.3 million in 2021, then tumbled by 38.19% to $2.6 million in 2022, then decreased by 7.46% to $2.4 million in 2023, then fell by 27.96% to $1.8 million in 2024, then dropped by 4.51% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.6 million for Q2 2025, and $2.0 million during Q1 2025.